Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SQNM's test is the most expensive and Ariosa's is the cheapest one.
ZTS/PFE quiz
Only thing I can think of is the expected Pfizer's next move - voluntary exchange offer with discount on ZTS share price.
Amgen's T-Vec in melanoma
Amgen's T-Vec in melanoma
Xarelto gets CHMP recommendation for ACS indication:
http://press.healthcare.bayer.com/en/press/news-details-page.php/14953/2013-0172
In this case you'll be delighted to read the PwC 2012 patent litigation study:
http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml
Dolutegravir will take share from Isentress in treatment-experienced patients but as you said, its combo with Epzicom isn't an attractive option to Stribild in first line. Still, Isentress annual sales were about $1.5B last year.
The development of anti-drug antibodies has indeed been associated with worse efficacy but also with hypersensitivity reactions, that in very rare cases could result in anaphylaxis and death. This serious systemic reaction is usually quick i.e hours after injection/infusion. Still, when a patient shows hypersensitivity reaction that is getting worse (like the Swedish patient), it is alerting and treatment should be stopped and anti-drug antibodies test should be perform. It's true that usually these anti-drug antibodies don't kill but keep giving the drug to patients with high titre values is harming anyway because the drug isn't working and their condition worsen (increased disability progression, relapse rate, and MRI lesion formation).
Re: MS Patient Dies From Anti-Drug Antibodies
This attitude would have saved that patient:
The only mention of the Procognia-UniTargeting FoB collaboration update (in English), is this words deficient paragraph:
BTW, I see that GSK has another Lp-PLA2 inhibitor from the same family as darapladib (also from HGS), completed phase II in atherosclerosis and active in AD.
http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=LP2105521&studyId=7D1AFC17-B7CE-4B6E-9179-DFF5E8FA1163&compound=rilapladib
DDXS / GSK / darapladib
The failure of ANTH's drug in ACS isn't a good sign for darapladib probably, although it targets a different class of phospholipase A2 enzyme but same superfamily of pro-inflammatory enzymes associated with atherosclerosis.
Do you know if this plac test Clevelad lab offers is DDXS'?
http://clevelandheartlab.com/Uploads/Public/Documents/Lp-PLA2%20One-pager_v1.pdf
Give it time lad, I'll get there one day :)
I am, for all intents and purposes, a Botox fan
FoB collaboration
Procognia collaborates with a Sweedish comp - Uni Targeting Research for the development of biosimilar and biobetter drugs. Today they published (only in Hebrew for now) preclinical results about their version of Humira.
It was on a local report that the board of directors hired Citigroup because they are frustrated and want to sell the company. So we know it's for sale but what about the buyer? rumors from PLX were they want $1B but I think will take less.
Perhaps this will result in an off-label use of sofo+dacla combo in GT3 patients.
You are thinking of patients while GILD is thinking of making max profit.
I'm not even sure the 7% difference doesn't show stst-sig non inferiority to SOC and while I agree that the right way would be to separate GT2 and 3 and find a better combo for GT3, I think that in light of SOC, no options, no resistance, the FDA will approve.
I sure hope so :)
If i were a GT3 patient, i'd still rather try the 12-weeks Sofo/Riba oral treatment first, knowing no resistance to sofo jeopardize my future treatment options in case i relapse.
The stock jumps some 24% at TASE now on buyout rumors
Rosetta Green was a spin-off from ROSG but ROSG sold almost all its stake for peanuts. MON is shopping/investing in Israel for the 4th time now (Beeologics, Evogene, abseeds).
Rosetta Green was a spin-off from ROSG but ROSG sold almost all its stake for peanuts. MON is shopping/investing in Israel for the 4th time now (Beeologics, Evogene, abseeds).